194 related articles for article (PubMed ID: 38549238)
1. Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.
Ciardullo S; Savaré L; Rea F; Perseghin G; Corrao G
Diabetes Metab Res Rev; 2024 May; 40(4):e3791. PubMed ID: 38549238
[TBL] [Abstract][Full Text] [Related]
2. Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.
Rea F; Ciardullo S; Savaré L; Perseghin G; Corrao G
Diabetes Res Clin Pract; 2021 Oct; 180():109035. PubMed ID: 34487757
[TBL] [Abstract][Full Text] [Related]
3. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
[TBL] [Abstract][Full Text] [Related]
5. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study.
Werkman NCC; Driessen JHM; Stehouwer CDA; Vestergaard P; Schaper NC; van den Bergh JP; Nielen JTH
Cardiovasc Diabetol; 2023 Jun; 22(1):160. PubMed ID: 37386427
[TBL] [Abstract][Full Text] [Related]
6. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.
McCormick TA; Kramer J; Liles EG; Amos Q; Martin JP; Adams JL
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38719507
[TBL] [Abstract][Full Text] [Related]
8. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
[TBL] [Abstract][Full Text] [Related]
9. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
Cardoso P; Young KG; Nair ATN; Hopkins R; McGovern AP; Haider E; Karunaratne P; Donnelly L; Mateen BA; Sattar N; Holman RR; Bowden J; Hattersley AT; Pearson ER; Jones AG; Shields BM; McKinley TJ; Dennis JM;
Diabetologia; 2024 May; 67(5):822-836. PubMed ID: 38388753
[TBL] [Abstract][Full Text] [Related]
10. Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team.
Champion M; Wills Avila G; Garcia AE; Álvarez Delgado FM; Valdez CA
J Prim Care Community Health; 2024; 15():21501319241231398. PubMed ID: 38353180
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
Gorgojo-Martínez JJ; Serrano-Moreno C; Sanz-Velasco A; Feo-Ortega G; Almodóvar-Ruiz F
Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):129-137. PubMed ID: 28077257
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
13. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
[TBL] [Abstract][Full Text] [Related]
14. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.
Mahmoud F; Mullen A; Sainsbury C; Rushworth GF; Yasin H; Abutheraa N; Mueller T; Kurdi A
Eur J Clin Invest; 2023 Aug; 53(8):e13997. PubMed ID: 37002856
[TBL] [Abstract][Full Text] [Related]
16. Predictors of efficacy of Sodium-GLucose Transporter-2 inhibitors and Glucagon-Like Peptide 1 receptor agonists: A retrospective cohort study.
Scoccimarro D; Cipani G; Dicembrini I; Mannucci E
Diabetes Metab Res Rev; 2024 Feb; 40(2):e3727. PubMed ID: 37776322
[TBL] [Abstract][Full Text] [Related]
17. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
Blood AJ; Chang LS; Hassan S; Chasse J; Stern G; Gabovitch D; Zelle D; Colling C; Aronson SJ; Figueroa C; Collins E; Ruggiero R; Zacherle E; Noone J; Robar C; Plutzky J; Gaziano TA; Cannon CP; Wexler DJ; Scirica BM
Circulation; 2024 Jun; 149(23):1802-1811. PubMed ID: 38583146
[TBL] [Abstract][Full Text] [Related]
18. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
[TBL] [Abstract][Full Text] [Related]
20. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]